Sector Expert: Maxim Jacobs

Edison Investment Research

Image: Maxim Jacobs

Maxim Jacobs is director of healthcare research, North America, for Edison Research. He joined Edison from Guidepoint Global, where he was a director of survey and tracker research, conducting extensive primary research across healthcare markets. He also brings more than 15 years of experience in equities to the healthcare team. Previously he was a senior healthcare analyst and therapeutic sector head at Ridgemark Capital and Broadfin Capital, and a healthcare analyst at Mehta Partners. Maxim is a CFA charter holder and graduated magna cum laude with a BA in Economics from the University of Pennsylvania.



Recent Quotes

"SNSS' application for EU approval for vosaroxin in AML continues to progress"

— Maxim Jacobs, Edison Investment Research (3/15/17)
more >

"A phase 1b/2 study for SNSS' SNS-062 is expected to begin in H1/17."

— Maxim Jacobs, Edison Investment Research (2/16/17)
more >

"SNSS reported new data on SNS-062 and Qinprezo at the American Society of Hematology meeting in December 2016."

— Maxim Jacobs, Edison Investment Research (12/13/16)
more >

"Significant potential for SNSS remains in Europe where Qinprezo has data comparable to those used in other related approvals."

— Maxim Jacobs, Edison Investment Research (12/8/16)
more >

"ATNM's targeted radiation therapies offer the potential of highly selective tumour cell killing with low damage to the surrounding normal tissue and limited side effects."

— Maxim Jacobs, Edison Investment Research (11/17/16)
more >

"Significant potential remains in Europe where SNSS's Qinprezo has data comparable to those used in other related approvals."

— Maxim Jacobs, Edison Investment Research (11/17/16)
more >

"RXII recently announced that it has entered into an exclusive option agreement to acquire MirImmune."

— Maxim Jacobs, Edison Investment Research (10/25/16)
more >

"ATNM's targeted radiation therapies offer the potential of highly selective tumor-cell killing with low damage to the surrounding normal tissue and limited side effects."

— Maxim Jacobs, Edison Investment Research (10/20/16)
more >

more comments

"RGS has firmed up its strategy to partner its product opportunities for development and commercialization, allowing it to focus on early-stage product development."

— Maxim Jacobs, Edison Investment Research (10/20/16)
more >

"SNSS's SNS-062 Phase I/IIa is expected to begin around year-end."

— Maxim Jacobs, Edison Investment Research (10/20/16)
more >

"SNSS will be advancing the drug into a Phase Ib/II B-cell malignancy trial following these results."

— Maxim Jacobs, Edison Investment Research (9/16/16)
more >

"SNSS is an oncology company with a late-stage asset, potentially near European approval, as well as preclinical assets utilising promising targets, making it an attractive partner."

— Maxim Jacobs, Edison Investment Research (8/18/16)
more >

"ATNM's targeted radiation therapies offer the potential of highly selective tumour cell killing with low damage to the surrounding normal tissue and limited side effects."

— Maxim Jacobs, Edison Investment Research (8/18/16)
more >

"Initial results from a Phase 1a study of SNSS' BTK inhibitor SNS-062 will be reported in September."

— Maxim Jacobs, Edison Investment Research (8/3/16)
more >

"ATNM's targeted radiation therapies offer the potential of highly selective tumor cell killing with low damage to the surrounding normal tissue and limited side effects."

— Maxim Jacobs, Edison Investment Research (6/23/16)
more >

"SNSS has a late-stage asset, potentially near European approval, as well as preclinical assets utilizing promising targets, making it an attractive partner."

— Maxim Jacobs, Edison Investment Research (6/23/16)
more >

"Our valuation increase for SNSS reflects the encouraging results from the Qinprezo/Dacogen combination study."

— Maxim Jacobs, Edison Investment Research (6/22/16)
more >

"Significant potential remains in Europe for SNSS' Qinprezo."

— Maxim Jacobs, Edison Investment Research (4/21/16)
more >

— Maxim Jacobs, Edison Investment Research (4/18/16)
more >

"A Phase 2 trial with ATHX's MultiStem in AMI is underway."

— Maxim Jacobs, Edison Investment Research (3/24/16)
more >

"ATHX's deal with Healios increases milestone payments and royalties."

— Maxim Jacobs, Edison Investment Research (3/4/16)
more >

"ATHX has a Phase 2 trial with MultiStem in acute myocardial infarction underway with data expected in H2/16"

— Maxim Jacobs, Edison Investment Research (2/25/16)
more >

"ATHX's recent Phase 2 data in stroke indicated strong trends in favor of MultiStem across multiple endpoints."

— Maxim Jacobs, Edison Investment Research (12/14/15)
more >

"We maintain our estimate of $217M in peak sales in RLMD's BuTab in both the chronic pain and the opioid dependence markets."

— Maxim Jacobs, Edison Investment Research (12/10/15)
more >

"ATHX's new partnership for commercialization of MultiStem in Japan could be even more lucrative."

— Maxim Jacobs, Edison Investment Research (10/21/15)
more >

"ATHX provided much needed data on its Phase 2 ischemic stroke trial."

— Maxim Jacobs, Edison Investment Research (8/19/15)
more >

fewer comments


Due to permission requirements, not all quotes are shown.